Received: 23 April 2020
Accepted: 29 June 2020
First Online: 14 July 2020
Ethics approval and consent to participate
: According to the French legislation, this study was approved by the Ethics Committee of the French Society of Infectious Diseases (<i>Société de Pathologie Infectieuse de Langue Française</i>), n°2019-0902, and declared to the French national data protection commission (<i>Commission Nationale de l’Informatique et des Libertés</i>, <i>CNIL</i>), n°19-213.
: Not applicable.
: bioMerieux SA provided IUO tests for the study. bioMerieux SA did not interfere with data collection and analysis, nor with manuscript preparation. Dr. Julien Textoris participated in the elaboration of the protocol.SK declares grants from bioMérieux and lecture fees and conference invitations from bioMérieux, MSD, and Accelerate Diagnostics.CM received lecture fees from bioMerieux SA.ATD and NG report no conflicts of interest.VC reports personal fees from Accelerate Diagnostics, Astellas, bioMérieux, Correvio, Curetis, Eumédica, Menarini, Mylan, Pfizer, and Sanofi.LA received lecture fees from Pfizer, MSD, Biocodex, and Biomerieux.All authors have submitted the ICMJE form for disclosure of potential conflicts of interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.